ACADIA Pharmaceuticals Inc. (ACAD)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fireside Chat: Monday, March 2, 2026 at 11:10 a.m. Eastern Time in Boston, MA The Citizens Life Sciences Conference Fireside Chat: Wednesday, March 11, 2026 at 1:05 p.m. Eastern Time in Miami Beach, FL Live webcasts will be accessible on the company's website, acadia.com, under the investors section.

Rhumbline Advisers boosted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 6.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 391,549 shares of the biopharmaceutical company's stock after acquiring an additional 24,463 shares during the period.

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSA Capital Partners LLP raised its position in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 210.1% during the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 75,902 shares of the biopharmaceutical company's stock after purchasing an additional 51,428 shares during the period. GSA Capital Partners LLP's holdings in

LSV Asset Management decreased its position in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 91.8% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 17,200 shares of the biopharmaceutical company's stock after selling 192,800 shares during the quarter. LSV Asset Management's holdings in ACADIA

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twenty ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until May 24, 20.

Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.

Class A shares of the Alger Weatherbie Specialized Growth Fund outperformed the Russell 2500 Growth Index during the fourth quarter of 2025. Natera, Inc., ACADIA Pharmaceuticals Inc., and Glaukos Corp were among the top contributors to performance. FirstService Corp, AAR CORP., and Kratos Defense & Security Solutions, Inc. were among the top detractors from performance.

ACAD expects a negative CHMP opinion on trofinetide marketing application for Rett syndrome, likely delaying a potential EU approval.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on its Marketing Authorization Application (MAA) for trofinetide for the treatment of Rett syndrome, following its recent CHMP oral explanation. Subject to the outcome of the CHMP vote in February, Acadia intends to request a re-examination of the opinion b.

Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Exploring the Investment Strategies of John Hussman (Trades, Portfolio) in Q4 2025 John Hussman (Trades, Portfolio) recently submitted the 13F filing for the f

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?

Hussman Strategic Advisors Inc. acquired a new position in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 126,000 shares of the biopharmaceutical company's stock, valued at approximately $2,689,000. Hussman Strategic Advisors Inc. owned about 0.07%

SG Americas Securities LLC grew its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 613.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 39,680 shares of the biopharmaceutical company's stock after acquiring an additional 34,118 shares during the quarter. SG Americas Securities LLC's